HopeStage
Back to all studies
CompletedNCT00969618

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Researchers studied atomoxetine, tracking side effects to assess long-term safety and tolerability in adults with ADHD.

Medication studyAges 18+Japan
The study in practice

Understand this study

What did researchers investigate?

Researchers studied atomoxetine, tracking side effects to assess long-term safety and tolerability in adults with ADHD.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Aichi and 11 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateNovember 2009
Recruitment status
Completed
Enrollment listed in the registry
211
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Japan
Age range
Over 18 Years
Official registry ID
NCT00969618
Official title
Show the full official title

Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Aichi · Chiba · Fukushima

9 more locations
  • Hokkaido
  • Hyōgo
  • Kanagawa
  • Kumamoto
  • Kyoto
  • Nara
  • Osaka
  • Saitama
  • Tokyo
FAQ

Questions about this study

What did researchers investigate?

Researchers studied atomoxetine, tracking side effects to assess long-term safety and tolerability in adults with ADHD.

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine.

Who was this study for?

This study was for people with ADHD. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me